PCSK9 inhibitors
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces LDL receptor recycling, leading to a decrease of low-density lipoprotein cholesterol (LDL-C) receptors on the surface of hepatocytes an...
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2015-04-01
|
| coleção: | Swiss Medical Weekly |
| Assuntos: | |
| Acesso em linha: | https://www.smw.ch/index.php/smw/article/view/2023 |